Hostname: page-component-cd9895bd7-7cvxr Total loading time: 0 Render date: 2024-12-27T07:04:44.444Z Has data issue: false hasContentIssue false
  • English
  • Français

Substance P-like Immunoreactivity and Analgesic Effects of Vibratory Stimulation on Patients Suffering From Chronic Pain

Published online by Cambridge University Press:  18 September 2015

Régis Guieu ,
Marie-Françoise Tardy-Gervet  and
Pierre Giraud
Régis Guieu*
Affiliation:
Laboratoire de Biochimie, UER de Medecine, secteur Nord, URA CNRS 1455, Marseilles, France (R.G.); Laboratoire de Neurobiologie Humaine, Université de Provence, URA CNRS 372, Marseilles, France (M.-F.T.-G.); UER de Medecine, secteur Nord. INSERM U297. Marseilles. France (P.G.)
Marie-Françoise Tardy-Gervet
Affiliation:
Laboratoire de Biochimie, UER de Medecine, secteur Nord, URA CNRS 1455, Marseilles, France (R.G.); Laboratoire de Neurobiologie Humaine, Université de Provence, URA CNRS 372, Marseilles, France (M.-F.T.-G.); UER de Medecine, secteur Nord. INSERM U297. Marseilles. France (P.G.)
Pierre Giraud
Affiliation:
Laboratoire de Biochimie, UER de Medecine, secteur Nord, URA CNRS 1455, Marseilles, France (R.G.); Laboratoire de Neurobiologie Humaine, Université de Provence, URA CNRS 372, Marseilles, France (M.-F.T.-G.); UER de Medecine, secteur Nord. INSERM U297. Marseilles. France (P.G.)
*
Laboratoire de Neurobiologie Humaine, Universite de Provence, URA CNRS 372, Avenue Escadrilire Normandie Nienien 13397 Marseilles Cedex 13 (France)
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

By applying vibratory stimulation to patients suffering from pain, it is possible to set up an inhibitory control on the pain pathways which is based on the activation of large-sized afferent fibres. The exact mechanisms responsible for these analgesic effects still remain to be determined, however. For this purpose, we investigated in the present study whether or not the analgesic effects were accompanied by a decrease in the CSF substance P-like immunoreactivity levels (SPLI) of seven patients suffering from chronic pain, who were fitted with a ventriculo-peri-toneal drain. The SPLI levels were determined before and after 30-min vibratory stimulation sessions. The results show that the SPLI levels decreased as the result of the vibration, but this decrease seems to be too slight to account for the pain relief obtained.

Type
Research Article
Information
Canadian Journal of Neurological Sciences , Volume 20 , Issue 2 , May 1993 , pp. 138 - 141
Copyright
Copyright © Canadian Neurological Sciences Federation 1993

References

1.Guieu, R, Tardy-Gervet, MF, Roll, JP. Vibration applied simultane-ously with transcutaneous electrical nerve stimulation as means of treating chronic pain. Eur J Neurosci 1989; suppl. 2: 170.Google Scholar
2.Guieu, R, Tardy-Gervet, MF, Blin, O, Pouget, J. Pain relief achieved by transcutaneous electrical nerve stimulation and/or vibratory stimulation in a case of painful legs and moving toes. Pain 1990; 42: 43–48.CrossRefGoogle ScholarPubMed
3.Guieu, R, Tardy-Gervet, MF, Roll, JP. Analgesic effects of vibration and transcutaneous electrical nerve stimulation applied separately and simultaneously to patients with chronic pain. Can J Neurol Sci 1991; 18: 113–119.CrossRefGoogle ScholarPubMed
4.Lundeberg, T. Vibratory stimulation for the alleviation of chronic pain. Acta Physiol Scand 1983; suppl. 523: 1–51.Google ScholarPubMed
5.Lundeberg, T. The pain suppressive effect of vibratory stimulation and transcutaneous electrical nerve stimulation (TENS) as compared to aspirin. Brain Res 1984a; 294: 201–209.CrossRefGoogle ScholarPubMed
6.Lundeberg, T. Long-term results of vibratory stimulation as a pain relieving measure for chronic pain. Pain 1984b; 20: 13–23.CrossRefGoogle ScholarPubMed
7.Lundeberg, T, Abrahamsson, P, Bondesson, L, Haker, E. Effect of vibratory stimulation on experimental and clinical pain. Scand J Rehab Med 1988; 20: 149–159.Google ScholarPubMed
8.Lundeberg, T, Ottoson, D, Hakansson, S, Meyerson, BA. Vibratory stimulation for the control of intractable chronic orofacial pain. In: Bonica et al., eds. Advances in Pain Research and Therapy, Vol. 5. New-York: Raven Press, 1983; 555–561.Google Scholar
9.Ekblom, A, Hansson, PT. Extra segmental transcutaneous electrical nerve stimulation and mechanical vibratory stimulation as compared to placebo for the relief of acute orofacial pain. Pain 1985; 23: 223–229.CrossRefGoogle Scholar
10.Hansson, P, Ekblom, A. Afferent stimulation-induced pain relief in acute oro-facial pain and its failure to induce sufficient pain reduction in dental and oral surgery. Pain 1984; 20: 273–278.CrossRefGoogle ScholarPubMed
11.Lundeberg, T, Nordemar, R, Ottosson, D. Pain alleviation by vibratory stimulation. Pain 1984; 20: 25–44.CrossRefGoogle ScholarPubMed
12.Ottosson, D, Ekblom, A, Hansson, P. Vibratory stimulation for the relief of pain of dental origin. Pain 1981; 10: 37–45.CrossRefGoogle Scholar
13.Guieu, R, Tardy-Gervet, MF, Giraud, P. Met-enkephalin and beta-endorphin are not involved in the analgesic action of transcutaneous vibratory stimulation. Pain 1992; 48: 83–88.CrossRefGoogle Scholar
14.Hansson, P, Ekblom, A, Thomson, M, Fjellner, B. Influence of naloxone on relief of acute orofacial pain by transcutaneous electrical nerve stimulation or vibration. Pain 1986; 24: 323–329.CrossRefGoogle ScholarPubMed
15.Lundeberg, T. Naloxone does not reverse the pain-reducing effect of vibratory stimulation. Acta Anesthesiol Scand 1985; 29: 212–216.CrossRefGoogle Scholar
16.Salter, MW, Henry, JL. Evidence that adenosine mediates the depression of spinal dorsal horn neurones induced by peripheral vibration in the cat. Neuroscience 1987; 22: 631–650.CrossRefGoogle ScholarPubMed
17.Bossut, D, Frenk, H, Mayer, DJ. Is substance P a primary afferent neurotransmitter for nociceptive input? IV 2-amino 5-phospho-novalerate (APV) and (D-Pro2, D-Trp7,9)-substance P exert different effects on behaviors induced by intrathecal substance P, strychnine and kainic acid. Brain Res 1988; 455: 247–253.CrossRefGoogle ScholarPubMed
18.Frenk, H, Bossut, D, Urea, G, Mayer, D. Is substance P a primary afferent neurotransmitter for nociceptive input? Analysis of pain-related behaviors resulting from intrathecal administration of substance P and 6 excitatory compounds. Brain Res 1988; 455: 223–231.CrossRefGoogle ScholarPubMed
19.Henry, JL. Effects of substance P on functionally identified units in cat spinal cord. Brain Res 1976; 114: 439–451.CrossRefGoogle ScholarPubMed
20.Kellstein, DE, Price, DD, Hayes, RL, Mayer, DJ. Evidence that substance P selectively modulates C-fiber-evoked discharges of dorsal horn nociceptive neurons. Brain Res 1990: 526; 291–298.CrossRefGoogle ScholarPubMed
21.Krivoy, WA, Couc, JR, Henry, JL, Stewart, JM. Synaptic modulation by substance P. Fed Proc Am Soc Exp Biol 1979; 38: 2344–2347.Google ScholarPubMed
22.Piercey, MF, Dobry, PJK, Schroeder, LA, Einspahr, FJ. Behavioral evidence that substance P may be a spinal cord sensory neurotransmitter. Brain Res 1981; 210: 407–412.CrossRefGoogle ScholarPubMed
23.Hirota, N, Kuraishi, Y, Hino, Y, Sato, Y, Satoh, M, Takagi, H. Metenkephalin and morphine but not dynorphin inhibit noxious stimuli-induced release of substance P from rabbit dorsal horn in situ. Neuropharmacology 1985; 24: 567–570.CrossRefGoogle Scholar
24.Kantner, RM, Kirby, ML, Goldstein, BD. Increase in substance P in the dorsal horn during a chemogenic nociceptive stimulus. Brain Res 1985; 338: 196–199.CrossRefGoogle ScholarPubMed
25.Kuraishi, Y, Hirota, N, Sugimoto, M, Satoh, M, Takagi, H. Effects of morphine on noxious stimuli-induced release of substance P from rabbit dorsal horn in vivo. Life Sci 1983; 33: 693–696.CrossRefGoogle ScholarPubMed
26.Jessel, TM, Mudge, AW, Leeman, SE, Yaksh, TL. Release of substance P and somatostatin in vivo from primary afferent terminals in mammalian spinal cord. Neurosci Abstr 1979; 5: 611.Google Scholar
27.Von, Knorring L, Almay, BGL, Johansson, F, Schuber, G, Terenius, L. Changes in CSF endorphins and monoamine metabolites related to treatment with high frequency transcutaneous electrical nerve stimulation. Nord J Psychiat 1985; 39 suppl. 11: 83–90.Google Scholar
28.Yashpal, K, Wright, DM, Henry, JL. Substance P reduces tail-flick latency: implications for chronic pain syndromes. Pain 1982; 14: 155–167.Google Scholar
29.Salter, MW, Henry, JL. Physiological characteristics of responses of wide dynamic range spinal neurones to cutaneously applied vibration in the cat. Brain Res 1989; 507: 69–84.CrossRefGoogle Scholar
30.Salter, MW, Henry, JL. Differential responses of nociceptive vs non-nociceptive spinal dorsal horn neurones to cutaneously applied vibration in the cat. Pain 1990; 40: 311–322.CrossRefGoogle ScholarPubMed
31.Wall, PD, Cronly-Dillon, JR. Pain, itch, and vibration. Arch Neurol 1960; 2: 365–375.CrossRefGoogle ScholarPubMed
32.Kowalski, C. Etude de la régulation de la biosynthèse et de la sécrétion des enképhalines dans les neurones striataux de rat en culture primaire, Thèse de doctorat, Marseille, 1990.Google Scholar
33.Hosobuchi, Y, Emson, PC, Iversen, LL. Elevated cerebrospinal fluid substance P in arachnoiditis is reduced by systemic administration of morphine. In: Costa, E, Trabucchi, M, eds. Regulatory Peptides. From Molecular Biology to Function. New-York: Raven Press, 1982; 497–500.Google Scholar
34.Tamsen, A, Sakurada, T, Wahlström, A, Terenius, L, Hartvig, P. Postoperative demand for analgesics in relation to individual levels of endorphins and substance P in cerebrospinal fluid. Pain 1982; 13: 171–183.CrossRefGoogle ScholarPubMed
35.Almay, BGL, Johansson, F, Von, Knorring L, Sakurada, T, Terenius, L. Long term high frequency transcutaneous electrical nerve stimulation (hi-TNS) in chronic pain. Clinical response and effects on CSF endorphins, monoamine metabolites, substance P-like immunoreactivity (SPLI) and pain measures. J Psychosom Res 1985; 3: 247–257.Google Scholar
36.Sjostrom, S, Tamsen, A, Hartvig, P, Folkesson, R, Terenius, L. Cerebrospinal fluid concentrations of SP and Met-enkephalin during surgery and patient-controlled analgesia. Anesth Analg 1988; 67: 976–981.Google Scholar
37.Almay, BGL, Johansson, F, Von, Knorring L, Le, Greves P, Terenius, L. Substance P in CSF of patients with chronic pain syndromes. Pain 1988; 33: 3–9.CrossRefGoogle ScholarPubMed
38.Brownstein, MJ, Mroz, EA. Tappaz, ML, Leeman, SE. On the origin of substance P and glutamic decarboxylase (GAD) in the substantia nigra. Brain Res 1977; 135: 315–323.CrossRefGoogle ScholarPubMed
39.Gale, K, Hong, JS, Guidotti, A. Presence of substance P and GABA in separate striato-nigral neurons. Brain Res 1977; 136: 71–375.CrossRefGoogle Scholar